Jeffrey S. Ramsay

Davis Polk advised the joint book-running managers and the initial purchasers in a Rule 144A/Regulation S offering of $250 million principal amount of 3.000% senior secured notes due…

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…

Davis Polk advised the underwriters in connection with the offering of $1.25 billion aggregate principal amount of 1.125% bonds due October 7, 2030 issued by the Province of Ontario. The…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €6.25 billion aggregate principal amount of notes by Medtronic Global…

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of $500 million aggregate principal amount of its floating-rate senior notes due 2023, under its medium-term…

Davis Polk advised the representative of the underwriters in connection with an SEC-registered offering by YUM! Brands, Inc. of $1.05 billion aggregate principal amount of 3.625%…

Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of (i) $1.25 billion aggregate principal amount of its 0.450% senior notes due 2023 and (ii) $1 billion…

Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its 0.75% senior notes due 2023, $1 billion…

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…